HIT Consultant November 10, 2021
Jasmine Pennic

What You Should Know:

CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired MedActionPlan®, a New Jersey-based provider of medication safety and adherence technology and patient education.

– MedActionPlan programs have been proven to improve adherence, reduce healthcare costs, and increase patient satisfaction.

Acquisition Benefits for CareDx

The acquisition complements CareDx’s goal of connecting offerings for transplant patients, including:

– MedActionPlan PRO: a medication management and adherence platform to simplify post-transplant medication regimens. It is used by more than 100 healthcare systems, with the majority being...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mergers & Acquisitions / JV, Pharma / Biotech, Precision Medicine, Trends
Estonian Biobank to Sequence 10,000 Genomes as Part of Precision Medicine Project
Precision Immune Start-Up Mirador Launches with $400M+
The future of companion diagnostic (CDx) development: Why commercialization is key
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Precision Medicine Startup Mirador Unveils $400M for R&D of New I&I Drugs

Share This Article